Hca Healthcare, INC Form 4 insider transactions

Jennifer Berres, SVP & Chief Human Resources Officer of HCA Healthcare, reports the acquisition and disposal of company stock, including sales at weighted average prices of $322.955 and $322.3061.

Jennifer Berres, SVP & Chief Human Resources Officer at HCA Healthcare, reports the exercise of stock appreciation rights and disposition of shares to cover tax obligations.

SVP & Chief Nurse Executive of HCA Healthcare, Sammie S. Mosier, reports the vesting and conversion of restricted stock units into common stock, along with a disposition of shares to cover tax obligations.

HCA Healthcare's Senior Vice President and Controller, Christopher F. Wyatt, was granted 3,575 stock appreciation rights.

Sammie S. Mosier, a Senior Vice President and Chief Nurse Executive at HCA Healthcare, acquired 4,469 stock appreciation rights on January 28, 2025.

HCA Healthcare's EVP & Chief Legal & Admin Officer, Michael R. McAlevey, acquired stock appreciation rights and disposed of common stock, according to a recent SEC filing.

HCA Healthcare's EVP and CFO, Mike Marks, was granted 15,639 stock appreciation rights on January 28, 2025, which vest in four equal annual installments starting January 28, 2026.

HCA Healthcare CEO Samuel Hazen was granted 74,620 stock appreciation rights on January 28, 2025, which vest in four equal annual installments starting January 28, 2026.

HCA Healthcare's Executive Vice President and COO, Jon M. Foster, was granted 16,756 stock appreciation rights on January 28, 2025.

Michael S. Cuffe, EVP and Chief Clinical Officer at HCA Healthcare, acquired 11,171 stock appreciation rights on January 28, 2025.

HCA Healthcare's Senior Vice President and Chief Human Resources Officer, Jennifer Berres, was granted 8,490 stock appreciation rights on January 28, 2025.

HCA Healthcare's Senior Vice President and Chief Ethics Officer, Kathleen M. Whalen, sold 1,474 shares of common stock at a price of $357.99 per share on November 14, 2024.

HCA Healthcare's EVP and COO, Jon M. Foster, reported multiple transactions involving company stock, including acquisitions, disposals, and transfers to trusts.

Phillip G. Billington, SVP-Internal Audit Services at HCA Healthcare, reported the acquisition and disposal of company stock and stock appreciation rights.

HCA Healthcare's Group President, Erol R. Akdamar, reported multiple transactions involving company stock, including the acquisition of shares through stock appreciation rights and subsequent sales.

HCA Healthcare's SVP & Chief Ethics Officer, Kathleen M. Whalen, reported the acquisition of 4,710 shares and the disposal of 3,236 shares of common stock, along with the vesting of stock appreciation rights.

Patricia Elcan, a director with indirect ties to HCA Healthcare, executed a series of transfers involving units of Hercules Holding II to family trusts, with no net change in her overall beneficial ownership.

Michael S. Cuffe, EVP and Chief Clinical Officer of HCA Healthcare, exercised stock appreciation rights and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Mike Marks, EVP and CFO of HCA Healthcare, reports changes in beneficial ownership of company stock due to gift transactions.

Samuel Hazen, CEO of HCA Healthcare, filed a Form 4 detailing changes in his beneficial ownership of company stock due to gift transactions.

Joseph A. Sowell III, SVP and Chief Development Officer of HCA Healthcare, reports changes in beneficial ownership of company stock due to gift transactions.

Group President Timothy McManus of HCA Healthcare, Inc. reports the exercise of stock appreciation rights and related stock transactions.

Kathleen Whalen, SVP & Chief Ethics Officer of HCA Healthcare, reports the acquisition and disposal of company stock and stock appreciation rights.

Deborah M. Reiner, SVP of Marketing & Communications at HCA Healthcare, reported the sale of 3,314 shares of common stock at a price of $359.9621 per share on July 29, 2024.

Christopher F. Wyatt, SVP & Controller of HCA Healthcare, reports the acquisition and disposal of common stock and stock appreciation rights on July 25 and July 29, 2024.

Kathryn A. Torres, SVP at HCA Healthcare, reported selling 1,857 shares of common stock at a price of $355.05 on July 25, 2024.

Kathleen M. Whalen, SVP & Chief Ethics Officer of HCA Healthcare, reports multiple transactions involving common stock and stock appreciation rights.

Kathryn A. Torres, SVP at HCA Healthcare, reported selling 1,863 shares of common stock at an average price of $326.1799 on May 15, 2024.

Joseph A. Sowell III, SVP and Chief Development Officer of HCA Healthcare, exercised stock appreciation rights and disposed of shares to cover tax obligations.

Jon M. Foster, EVP and COO of HCA Healthcare, reports transactions involving common stock and stock appreciation rights.